← All trials
NCT07284420
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2025
- Primary completion
- Mar 7, 2028
- Completion date
- Mar 7, 2028
- First posted
- Dec 16, 2025
- Last posted
- Dec 16, 2025
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- argenxLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.